MXCT - NASDAQ
MaxCyte, Inc.
$1.21
-0.22%MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
At a Glance
Live SnapshotMaxCyte, Inc. Management Team
Mr. Ali Soleymannezhad
Chief Commercial Officer
Compensation
$660,200
Mr. Douglas J. Swirsky CFA, CPA
Chief Financial Officer
Compensation
$700,557
Mr. Ronald Evan Holtz CPA, Ph.D.
Executive Vice President of Administration
Compensation
$649,385
Mr. Douglas Arthur Doerfler
Founder
Compensation
$2,338,348
Mr. Maher Masoud
President, Chief Executive Officer & Executive Director
Compensation
$990,004
Ms. Ana-Paula Martins Fernandes
Senior Vice President of Global Sales
Ms. Jill Mayer
Senior Vice President of Human Resources
Mr. Jay Gelfman
Senior Vice President of Operations
Mr. David Sandoval
Senior Vice President, General Counsel & Corporate Secretary
Mr. Jack Horgan
Vice President of Corporate Development
MaxCyte, Inc. Insider Positioning
During the last 12 months, insiders have purchased $1.02M and sold $31K worth of MXCT shares, resulting in $985K of net buying activity.
3 Months
0
0.00
10.1K
8.27K
-8K
-$8K
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
609.0K
1.02M
10.7K
22.38K
+994K
+$994K
Top Buyers
Erck Stanley C
Director
$244K
Douglas Richard
Director
$218K
Brooke William W
Director
$172K
Collins Cynthia
Director
$107K
Johnston John Joseph
Director
$107K
Top Sellers
Hemrajani Rekha
Director
$22K
Swirsky Douglas J
Officer: Chief Financial Officer
$8K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $985K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider buyers vs. 2 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
MXCT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | June 17, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 28, 2025 | June 18, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 26, 2024 | June 11, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 28, 2023 | June 22, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | May 26, 2022 | June 29, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | October 01, 2021 | October 29, 2021 | 2021 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.